Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
FierceBiotech4d
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
FiercePharma4d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
Amgen's muscular disorder drug meets main goal in late-stage study
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...
BioSpace4d
Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, But Analysts See Mixed Results
Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...
Analyst Expectations For Amgen's Future
Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...
Institutional investors may overlook Amgen Inc.'s (NASDAQ:AMGN) recent US$7.9b market cap drop as long-term gains remain positive
No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 4.4% ...